Amgen Inc

Amgen Announces Dividend and Q2 Results Amid Market Volatility

Amgen Inc. has announced a third quarter dividend and will report its second quarter financial results, despite market volatility, with its focus on innovative medicines and patient outcomes driving long-term growth prospects.

Jake Connors

02/08/2025, 16:13

2 minutes to read

Amgen Set to Release Q2 Financials Amid Market Challenges and Growth Opportunities in Biotech

Amgen is set to release its second quarter financial results on August 5, 2025, amidst market leading artists, and the theme parkour Street characters. 2 Date: 2025/07-07T00:55:00.000Z Source: www.finanews.com

Sands China’s shares price-Part of Ex…

Jake Connors

01/08/2025, 12:51

2 minutes to read

Amgen Inc. Shows Market Resilience with Stable Stock Amid Biotech Challenges

Amgen Inc. has demonstrated resilience in a challenging market, driven by its commitment to innovative medicines and strong market presence, positioning it for continued growth and success.

Samantha Roth

26/07/2025, 09:41

2 minutes to read

Amgen Inc. Announces Promising Phase 2 Results for MariTide, Boosting Investor Confidence

Amgen Inc. has made significant strides in research and development, unveiling promising results for its MariTide treatment and solidifying its position as a leader in the biotechnology industry.

Samantha Roth

05/07/2025, 13:29

2 minutes to read

Amgen Inc. Stock Soars on Successful Gastric Cancer Trial Results

Amgen Inc.’s stock price has surged due to positive news from its clinical trials, particularly the Phase 3 FORTITUDE-101 trial, which demonstrated the effectiveness of bemarituzumab in treating gastric cancer.

Samantha Roth

03/07/2025, 13:12

2 minutes to read

Amgen’s MariTide Study Shows Promising Weight Loss Results Despite Initial Stock Dip

Amgen’s experimental weight-loss drug MariTide has yielded promising results in a phase 2 study, with patients achieving significant weight loss without plateauing, despite a temporary dip in the company’s share price.

Samantha Roth

24/06/2025, 15:50

2 minutes to read

Amgen Highlights Strategic Vision at Goldman Sachs Conference Amid Dow Jones Uptrend

Amgen’s presentation at the Goldman Sachs conference comes as the broader market experiences a welcome uptrend, with the Dow Jones index rising 0.964% since the start of 2025.

Jake Connors

12/06/2025, 16:16

2 minutes to read

Amgen to Highlight Leadership at Jefferies Global Healthcare Conference

Amgen will showcase its leadership expertise at the Jefferies Global Healthcare Conference, providing investors and stakeholders with valuable insights into the company’s strategic direction and market outlook.

Samantha Roth

02/06/2025, 00:10

2 minutes to read

Amgen Secures UK Approval for TEPEZZA, Revolutionizing Thyroid Eye Disease Treatment

Amgen has secured marketing authorization in the UK for its TEPEZZA treatment, marking a major milestone in the fight against thyroid eye disease.

Jake Connors

07/05/2025, 21:11

2 minutes to read

Amgen Shatters Expectations with Record-Breaking Q1 2025 Earnings

Amgen’s Q1 2025 earnings report exceeded expectations, with top-line growth driven by key drugs, including biosimilar Stelara, solidifying the company’s momentum in the biotech space.

Vanessa Liu

03/05/2025, 23:56

2 minutes to read